StockNews.AI
CDTX
StockNews.AI
1 min

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025

1. Cidara to present CD388 Phase 2 data at ID Week 2025. 2. CD388 aims for universal prevention of influenza with a single dose. 3. CD388 received Fast Track Designation from the FDA in June 2023. 4. Positive Phase 2b results announced in June 2025. 5. Phase 3 ANCHOR trial initiated in September 2025.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical developments and FDA designation typically support stock performance. Historical examples include Vaxart and Moderna’s pricing jumps post-positive trial results.

How important is it?

The announcement of clinical data and strategic presentations are crucial for investor sentiment.

Why Short Term?

Upcoming presentation may lead to immediate investor interest and stock movement, similar to other biotech events.

Related Companies

MRNAPFENVAX
October 13, 2025 08:00 ET  | Source: Cidara Therapeutics, Inc. SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting late-breaking Phase 2 clinical data on its antiviral influenza candidate, CD388, during ID Week 2025, taking place October 19-22, 2025, in Atlanta, GA. Presentation details are summarized below: Presentation Title: A Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of CD388, a Novel Drug-Fc-Conjugate, for Prevention of Illness due to Influenza A and B in Healthy Unvaccinated Participants Presenter: James Alexander MD, MPH, FIDSASession: Extra, Extra! New Info on Treating and Preventing RSV and InfluenzaSession Location: B401-B402Session Date and Time: Monday, October 20, 2025, 3:15 PM - 4:30 PM ET About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com. INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com MEDIA CONTACT:Michael FitzhughLifeSci Communications(628) 234-3889mfitzhugh@lifescicomms.com

Related News